Skip to main content

Table 3 Factors associated with major comorbidities in RA patients in multivariate logistic regression analyses

From: Chinese Registry of rheumatoid arthritis (CREDIT): II. prevalence and risk factors of major comorbidities in Chinese patients with rheumatoid arthritis

  CVD Fragility fracture Malignancy
OR (95% CI) P OR (95% CI) P OR (95% CI) P
Female 0.70 (0.53–0.92) 0.01* 2.58 (1.59–4.18) <0.01* 1.26 (0.69–2.28) 0.45
Age, y 1.09 (1.07–1.10) <0.01* 1.05 (1.04–1.06) <0.01* 1.05 (1.03–1.07) <0.01*
RA duration  
 <5 years 1 (Ref) NA 1 (Ref) NA 1 (Ref) NA
 ≥5 years 1.33 (1.03–1.72) 0.03* 1.95 (1.44–2.63) <0.01* 0.97 (0.61–1.56) 0.91
RF/CCP+ 1.30 (0.90–.88) 0.17 1.31 (0.86–2.00) 0.22 1.95 (0.89–4.27) 0.10
DAS28 0.97 (0.90–1.05) 0.48 1.04 (0.95–1.13) 0.44 1.03 (0.89–1.19) 0.70
GC ever 1.11 (0.86–1.44) 0.42 1.05 (0.78–1.40) 0.75 0.61 (0.37–1.00) 0.05
MTX ever 0.77 (0.60–1.00) 0.05* 0.96 (0.72–1.28) 0.78 0.57 (0.35–0.91) 0.02*
bDMARDs 1.04 (0.64–1.69) 0.86 1.79 (1.16–2.76) <0.01* 0.15 (0.02–1.07) 0.06
  1. CVD cardiovascular disease, OR odds ratio, CI confidence interval, RA rheumatoid arthritis, NA not applicable, RF rheumatoid factor, CCP anti-citrullinated protein antibody, DAS28 disease activity score 28, GC glucocorticoid, MTX methotrexate
  2. * P < 0.05